Skip to content
Clinical Trials – home
FranceBack to France

Clinical trials in Quint-Fonsegrives – page 10

1 508 clinical trials in Quint-Fonsegrives, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Quint-Fonsegrives at a glance
1 508
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 508 trials in Quint-Fonsegrives

Open in trial search

Myelofibrosis+1

Recruiting

Study of pelabresib (DAK539) plus ruxolitinib versus placebo plus ruxolitinib in adult patients with myelofibrosis who are JAK‑inhibitor‑naive

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ruxolitinib
  • Sponsor:Novartis Pharma AG

Long‑Term Safety and Efficacy of RO7790121 in Adults with Moderate to Severe Rheumatoid Arthritis: Extension Study

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:RO7790121
  • Sponsor:F. Hoffmann-La Roche AG

Long‑Term Safety and Tolerability of Oral Fesoterodine in Adults with Hallucinations and Delusions Due to Alzheimer’s Disease Psychosis

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Betovumeline
  • Sponsor:Maplight Therapeutics Inc.

Cemsidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cemsidomide
  • Sponsor:C4 Therapeutics Inc.

Pumitamig Versus Durvalumab in Patients With Unresectable Stage III Non-Small Cell Lung Cancer Without Progression After Chemoradiation

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Remibrutinib in Chronic Spontaneous Urticaria for Patients Who Benefited from a Previous Remibrutinib Trial

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Remibrutinib
  • Sponsor:Novartis Pharma AG

Docetaxel and Apalutamide in Patients with Metastatic Hormone-Sensitive Prostate Cancer Who Did Not Have a Deep PSA Response After Initial Apalutamide Treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Apalutamide
  • Sponsor:Alianza Multidisciplinar Para La Investigacion De Los Tumores Genitourinarios Guard

INCA33890 With Standard Chemotherapy and Bevacizumab in First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Incyte Corp.

Bladder cancer

Recruiting

Durvalumab and Chemotherapy in Adults With Muscle-Invasive Bladder Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

Doxycycline for Asymptomatic Anal LGV Infection in Patients with Asymptomatic Anal LGV Infection

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Doxycycline Monohydrate
  • Sponsor:Centre Hospitalier Universitaire De Bordeaux

Nipocalimab in Adults with Moderate to Severe Systemic Lupus Erythematosus

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Nipocalimab
  • Sponsor:Janssen Cilag International

Neoplasm

Recruiting

Telisotuzumab Adizutecan for Locally Advanced or Metastatic Solid Tumors with MET Amplification in Patients 12 Years and Older

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Telisotuzumab adizutecan
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Other cities in France

The busiest research cities in the country

All 366 cities in France

Clinical research in Quint-Fonsegrives

What the registry says about research in the country

01 Urological Research

Extensive research focusing on bladder cancer treatments, including innovative therapies for both muscle-invasive and non-muscle-invasive cases. Studies also address prostate conditions, from benign hyperplasia to advanced cancer.

  • Advanced bladder cancer treatments
  • Prostate cancer therapy optimization
  • Kidney stone management

Novel approaches combine immunotherapy with targeted treatments to improve patient outcomes.

02 Oncology Studies

Comprehensive research into breast cancer treatments, particularly focusing on triple-negative and hormone receptor-positive variants. Studies evaluate new approaches in colon cancer management using circulating tumor DNA analysis.

  • Triple-negative breast cancer therapy
  • Colorectal cancer treatment
  • Lung cancer interventions

Investigations combine immunotherapy with traditional treatments for enhanced efficacy.

03 Specialized Medicine

Research addressing pulmonary conditions and specialized medical needs. Studies include evaluation of treatments for chronic obstructive pulmonary disease and migraine management in emergency settings.

  • COPD treatment optimization
  • Migraine therapy
  • Diabetic eye conditions

Focus on improving patient quality of life through innovative therapeutic approaches.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.